Fungal infection treatment developer Amplyx Pharmaceuticals had disclosed $142m in funding from investors including Pfizer and Lundbeckfonden Ventures.

Applied Ventures helped assay provider Ultivue close a $50m round while clean energy producer Sunseap has followed a $72m series D4 round with more corporate funding.

The food ordering app developer's largest shareholder, Info Edge, is set to sell $100m of shares in the proposed dual offering.

Renal care provider InterWell Health and skincare product manufacturer Make Essence both raised approximately $46m while Salesforce-backed JazzHR agreed a merger.

Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

Ant Group is the largest shareholder in the China-headquartered mobility services provider, which has chosen the US for its initial public offering.

Alphabet and Merck Group could exit the immunological and inflammatory disease therapy developer in an offering with an $86.3m placeholder target.

Carlyle Group has agreed to pay $435m for the biologics research technology provider, which has raised $86m from investors including Novo.